Advertisement
ABBV vs NVS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- ABBV has maintained steady upward momentum in recent weeks, supported by positive Phase 3 data for its migraine treatment and completion of a major acquisition.
- NVS experienced a sharp decline following two late-stage trial setbacks in early September 2026, offsetting earlier pipeline successes.
- AbbVie’s immunology portfolio, including Skyrizi and Rinvoq, continues to drive double-digit revenue growth, while Novartis faces scrutiny over acquired assets.
- ABBV trades near recent highs with a market capitalization exceeding $450 billion, compared to NVS around $260 billion amid heightened volatility.
- Both companies operate in the pharmaceutical sector with strong cash flows, but ABBV shows more consistent recent performance relative to NVS.
- Market sentiment favors ABBV due to pipeline catalysts and guidance raises, while NVS contends with investor concerns over deal execution.
Introduction
This comparison examines ABBV and NVS, two leading pharmaceutical companies with substantial market capitalizations and diversified portfolios. AbbVie focuses heavily on immunology and neuroscience, while Novartis emphasizes oncology, cardiovascular, and neuroscience therapies. The analysis targets institutional and retail investors seeking objective insights into relative performance, sector positioning, and recent catalysts within the healthcare space. Traders monitoring momentum shifts and long-term holders evaluating stability amid clinical developments will find the side-by-side review relevant for portfolio considerations.
AbbVie Overview and Recent Performance
AbbVie develops and commercializes therapies primarily in immunology, oncology, and neuroscience. In recent market activity, ABBV shares have traded near multi-month highs around $257, reflecting gains of approximately 3% over the past month and 15% year-to-date. Positive developments include Phase 3 success for atogepant in menstrual migraine prevention and the September 2026 completion of the $10.9 billion Apogee Therapeutics acquisition, which bolsters the immunology pipeline. Second-quarter results showed revenue of $16.99 billion, up over 10% year-over-year, prompting an upward revision to full-year guidance. These factors have supported constructive sentiment and relative outperformance versus broader market benchmarks in recent weeks.
Novartis Overview and Recent Performance
Novartis operates as a global pharmaceutical company with key franchises in oncology, immunology, and neuroscience. NVS shares have faced pressure in recent market activity, declining to the $137–$140 range after a sharp drop exceeding 10% in early September. Earlier positive Phase 3 data for remibrutinib in relapsing multiple sclerosis provided a brief lift, but subsequent failures of del-desiran in myotonic dystrophy and pelacarsen in cardiovascular outcomes weighed on the stock. Year-to-date performance remains positive at around 12–15%, though the one-month return turned negative amid the setbacks. The company has reaffirmed longer-term growth targets despite the near-term volatility.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. While Tickeron offers hundreds of AI Trading Bots capable of trading thousands of tickers across equities, options, and other instruments, only those demonstrating strong historical performance metrics, risk-adjusted returns, and alignment with current trends earn placement in this section. Available bots span diverse strategies, timeframes, and ticker sets, with performance statistics often ranging from double-digit annualized returns in favorable periods to varying drawdown profiles depending on market regimes. All bots feature distinct backtested statistics, win rates, and trade frequencies. Review the full collection on the Trending AI Robots page for detailed comparisons.
Head-to-Head Comparison
AbbVie and Novartis both generate substantial revenue from patented pharmaceuticals but differ in portfolio concentration and recent catalysts. AbbVie derives significant growth from its immunology segment, with Skyrizi and Rinvoq delivering consistent double-digit gains, whereas Novartis maintains broader exposure across oncology and cardiovascular areas. Recent momentum favors ABBV, which benefited from acquisition integration and positive trial readouts, contrasting with NVS volatility following clinical disappointments tied to acquired assets. Risk factors include patent cliffs for both, though AbbVie’s neuroscience expansion and Novartis’s BTK inhibitor progress represent offsetting opportunities. Sector exposure remains comparable within healthcare, yet market sentiment has tilted toward AbbVie’s execution stability over Novartis’s near-term pipeline uncertainty.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recent catalysts, and relative positioning, Tickeron’s AI models would currently assign a higher probabilistic preference to ABBV over NVS. AbbVie’s sustained revenue growth, guidance increases, and pipeline advancements provide more stable signals compared to Novartis’s recent trial volatility. This assessment reflects pattern recognition in historical and current data rather than forward guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and NVS is a Buy.
ABBV | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 4 | 11 | |
SMR RATING 1..100 | 1 | 33 | |
PRICE GROWTH RATING 1..100 | 55 | 56 | |
P/E GROWTH RATING 1..100 | 76 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (4) in the Pharmaceuticals Major industry is in the same range as ABBV (16). This means that NVS’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is in the same range as NVS (11). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as NVS (33). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
ABBV's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as NVS (56). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
NVS's P/E Growth Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (76). This means that NVS’s stock grew somewhat faster than ABBV’s over the last 12 months.
| ABBV | NVS | |
|---|---|---|
| RSI ODDS (%) | 7 days ago 39% | 4 days ago 38% |
| Stochastic ODDS (%) | 4 days ago 46% | 4 days ago 41% |
| Momentum ODDS (%) | 4 days ago 72% | 4 days ago 48% |
| MACD ODDS (%) | 4 days ago 67% | 4 days ago 57% |
| TrendWeek ODDS (%) | 4 days ago 63% | 4 days ago 54% |
| TrendMonth ODDS (%) | 4 days ago 55% | 4 days ago 40% |
| Advances ODDS (%) | 7 days ago 61% | 4 days ago 54% |
| Declines ODDS (%) | 21 days ago 46% | 20 days ago 43% |
| BollingerBands ODDS (%) | 4 days ago 46% | 4 days ago 33% |
| Aroon ODDS (%) | N/A | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 3 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).
- ABBV’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 3 bearish.
- NVS’s TA Score: 4 bullish, 5 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +0.14% price change this week, while NVS (@Pharmaceuticals: Major) price change was +3.63% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.47%. For the same industry, the average monthly price growth was -3.82%, and the average quarterly price growth was +12.03%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 23, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.47% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.29% | ||
| BMY - ABBV | 51% Loosely correlated | +2.21% | ||
| NVS - ABBV | 50% Loosely correlated | +1.32% | ||
| JNJ - ABBV | 49% Loosely correlated | +0.20% | ||
| AMGN - ABBV | 48% Loosely correlated | +2.11% | ||
| MRK - ABBV | 46% Loosely correlated | +0.54% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.